Clinical trials: Recurrent Tuberculosis, active
Tuberculosis
A Trial of 2 Disease-Modifying Drugs (Metformin and N-acetylcysteine ) to Promote TB Lung Function Recovery
Tuberculosis is a leading global cause of morbidity and mortality. Even if cured, a majority patients are left with bronchiectasis and fibrosis, permanent conditions that impair lung function.
- Trial name
- TB-MET-NAC (NCT07136987)
- Testing
- Metformin, N-Acetylcysteine (NAC) Treatment, Standard TB treatment
- Volunteers
- 1,104 people
- Sponsor
- Open Source Pharma Foundation
Pulmonary Tuberculosis
Short Course Regimen in Low Risk Active Tuberculosis- a Multicenter, Randomized, Active-controlled, Trial
Tuberculosis remains an important global health problem, and the world is currently not on track to end the TB epidemic by 2030.
- Trial name
- NCT06727864
- Testing
- 4-month regimen (2HERZ/2HRE), 6-month (2HERZ/4HRE)
- Where
- 8 sites in Taiwan
- Volunteers
- 270 people
- Sponsor
- Kaohsiung Veterans General Hospital.